Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Adalimumab, Infliximab And Etanercept Biosimilars Global Market Report 2023: Increasing Healthcare Access Bolsters Sector
January 11, 2023 04:48 ET
|
Research and Markets
Dublin, Jan. 11, 2023 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031" report has been added to ...
China Infliximab Market Investigation Report 2022: Sales 2017-2021, Major Manufacturers 2017-2021, Prices for Different Manufacturers 2021-2022 and Prospects 2022-2031
August 10, 2022 05:28 ET
|
Research and Markets
Dublin, Aug. 10, 2022 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Infliximab Market 2022-2031" report has been added to ResearchAndMarkets.com's offering. According to this market...
Global TNF Alpha Inhibitors Market Report 2022-2026 & 2031 Featuring Major Players - AbbVie, Amgen, J&J, UCB, Novartis, Pfizer, Merck & Co, Janssen Biotech, Ablynx, and Momenta Pharmaceuticals
August 04, 2022 07:04 ET
|
Research and Markets
Dublin, Aug. 04, 2022 (GLOBE NEWSWIRE) -- The "TNF Alpha Inhibitors Global Market Report 2022: By Drug, By Route, By Disease" report has been added to ResearchAndMarkets.com's offering. The global...
China's Infliximab Markets, 2016-2020 & 2021-2025 - Relevant Concepts, Sales, Major Manufacturers, Prices, Prospects
July 29, 2021 08:33 ET
|
Research and Markets
Dublin, July 29, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Infliximab Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. Infliximab is a human-mouse...
Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter
July 20, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
China National Medical Product Administration (NMPA) has granted Mabpharm approval to market INFLIXIMAB biobetter in China.Sorrento holds commercialization rights outside of China and intends to meet...
Global TNF Alpha Inhibitors Market Report 2020: Market is Expected to Recover and Reach $42.86 Billion in 2023 - Long-term Forecast to 2025 & 2030
March 29, 2021 04:53 ET
|
Research and Markets
Dublin, March 29, 2021 (GLOBE NEWSWIRE) -- The "TNF Alpha Inhibitors Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. The global...
Global $2.27 Billion Adalimumab, Infliximab and Etanercept Biosimilars Market to 2030
February 03, 2021 04:43 ET
|
Research and Markets
Dublin, Feb. 03, 2021 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to...
Global Gastrointestinal Drugs Markets, 2019-2020 & 2027: Acid Neutralizers, Antidiarrheal and Laxatives, Anti-inflammatory Drugs, Antiemetic and Antinauseants, Biologics
November 24, 2020 02:38 ET
|
Research and Markets
Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The "Gastrointestinal Drugs Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Class; Route of Administration; Application; Distribution...
Sorrento Announces Filing for Approval of Infliximab Biobetter Antibody by Its Partner Mabpharm in China
January 06, 2020 07:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics (Nasdaq: SRNE) announced today that its partner Mabpharm (HK:2181) filed recently a New Drug Application for the Infliximab...
American College of Rheumatology Encourages Safe Adoption of Biosimilars During FDA Public Hearing on CT-P13, a Proposed Biosimilar for Infliximab (Remicade)
February 10, 2016 14:43 ET
|
American College of Rheumatology
ATLANTA, Feb. 10, 2016 (GLOBE NEWSWIRE) -- During a public meeting held Tuesday by the Food and Drug Administration (FDA)'s Arthritis Advisory Committee to review the license application of CT-P13,...